Data as of Q4 2025 (Dec 31, 2025)

GENERAL ATLANTIC, L.P.

โ€ขCIK: 1017645โ€ขFiling: Q4 2025

**GENERAL ATLANTIC, L.P.** manages $2.9B across a concentrated portfolio of 13 positions. The fund exhibits significant conviction in financial and technology names, highlighted by a substantial $659.7M allocation to UBS. Further notable holdings include CHYM at $535.1M and BCDRF at $371.6M, underpinning a strategy focused on large-cap financial and industrial exposure. This top-heavy concentration suggests a directional, high-conviction approach to market cycles.

Total AUM
$2.9B
QoQ Performance
-13.8%
Positions
13
Top 10 Concentration
99.0%
Latest Filing
Q4 2025

Top Holdings Allocation

DLO
CHYM
XP
ALKT
ALHC
RVMD
PHAR
CNTA
DLO23.0%
CHYM18.6%
XP12.9%
ALKT9.6%
ALHC9.1%
RVMD7.8%
PHARVARIS7.8%
CNTA5.3%

๐Ÿ“ˆ Biggest Buys

NRIX
NURIX THERAPEUTICS
NEW
3.2% of portfolio
CHYM
CHIME
+10.7%
18.6% of portfolio
RVMD
REVOLUTION MEDICINES
+13.7%
7.8% of portfolio

๐Ÿ“‰ Biggest Sells

ALHC
ALIGNMENT HEALTHCARE
-45.8%
9.1% of portfolio
CNTA
CENTESSA PHARMACEUTICALS
-36.8%
5.3% of portfolio
โ€”
WEBULL
-99.3%
0.0% of portfolio
XP
XP, INC
-11.0%
12.9% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

AKRO
AKERO THERAPEUTICS
SOLD
$272.2M
RPRX
ROYALTY PHARMA
SOLD
$52.9M
ADAG
ADAGENE
SOLD
$7.5M
ALMS
ALUMIS
SOLD
$5.2M

Changes from Q3 2025

NEW1 new position
โ†‘2 increased
โ†“4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023